错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Somatic RIT1 delins in arteriovenous malformations hyperactivate RAS-MAPK signaling amenable to MEK inhibition

  • Friedrich G. Kapp,
  • Farhad Bazgir,
  • Nagi Mahammadzade,
  • Mehrnaz Mehrabipour,
  • Erik Vassella,
  • Sarah M. Bernhard,
  • Yvonne Döring,
  • Annegret Holm,
  • Axel Karow,
  • Caroline Seebauer,
  • Natascha Platz Batista da Silva,
  • Walter A. Wohlgemuth,
  • Aviv Oppenheimer,
  • Pia Kröning,
  • Charlotte M. Niemeyer,
  • Denny Schanze,
  • Martin Zenker,
  • Whitney Eng,
  • Mohammad R. Ahmadian,
  • Iris Baumgartner,
  • Jochen Rössler

摘要

Arteriovenous malformations (AVM) are benign vascular anomalies prone to pain, bleeding, and progressive growth. AVM are mainly caused by mosaic pathogenic variants of the RAS-MAPK pathway. However, a causative variant is not identified in all patients. Using ultra-deep sequencing, we identified novel somatic RIT1 delins variants in lesional tissue of three AVM patients. RIT1 encodes a RAS-like protein that can modulate RAS-MAPK signaling. We expressed RIT1 variants in HEK293T cells, which led to a strong increase in ERK1/2 phosphorylation. Endothelial-specific mosaic overexpression of RIT1 delins in zebrafish embryos induced AVM formation, highlighting their functional importance in vascular development. Both ERK1/2 hyperactivation in vitro and AVM formation in vivo could be suppressed by pharmacological MEK inhibition. Treatment with the MEK inhibitor trametinib led to a significant decrease in bleeding episodes and AVM size in one patient. Our findings implicate RIT1 in AVM formation and provide a rationale for clinical trials with targeted treatments.